



IMDRF International Medical
Device Regulators Forum

9
10
11
12
13
FINAL WORKING DRAFT

14
15
16
17
18 **Title:** Personalized Medical Devices – Regulatory Pathways

19
20 **Authoring Group:** IMDRF Personalized Medical Devices

21
22 **Date:** 10 August 2022

23
24
25 Tracey Duffy, IMDRF Chair

26
27
28 This document was produced by the International Medical Device Regulators Forum. There are
29 no restrictions on the reproduction or use of this document; however, incorporation of this
30 document, in part or in whole, into another document, or its translation into languages other than
31 English, does not convey or represent an endorsement of any kind by the International Medical
32 Device Regulators Forum.

33
34 Copyright © 2022 by the International Medical Device Regulators Forum.
35

36 **Table of Contents**

37

38 1.0 Introduction..... 4

39 2.0 Scope..... 5

40 3.0 References..... 5

41 4.0 Definitions..... 6

42 5.0 Decision Tree..... 9

43 6.0 Custom-made Medical Devices 10

44 7.0 Patient-matched Medical Devices..... 13

45 8.0 Adaptable Medical Devices 14

46 Appendix 1—Some considerations for medical devices produced using additive or subtractive

47 manufacturing 16

48 Appendix 2—Considerations for point-of-care manufacture of medical devices 21

49

50

51

52 **Preface**

53

54 The document herein was produced by the International Medical Device Regulators Forum
55 (IMDRF), a voluntary group of medical device regulators from around the world. The document
56 has been subject to consultation throughout its development.

57

58 There are no restrictions on the reproduction, distribution or use of this document; however,
59 incorporation of this document, in part or in whole, into any other document, or its translation
60 into languages other than English, does not convey or represent an endorsement of any kind by
61 the International Medical Device Regulators Forum.

62

Final Working Draft

63 1.0 Introduction

64 The primary purpose of this IMDRF guidance is to recommend a harmonized approach for the
65 application of existing regulatory pathways to medical devices that are intended for a particular
66 individual, and to identify special considerations for the regulation of each identified category of
67 personalized medical device (PMD). The adoption of consistent, harmonized requirements for
68 such medical devices will underpin a harmonized regulatory approach for controls on these types
69 of medical devices and offer significant benefits to the manufacturer, user, patient, and to
70 Regulatory Authorities (RAs). Eliminating differences between jurisdictions supports global
71 convergence, reduces the cost of gaining regulatory compliance and allows patients and
72 healthcare professionals earlier access to new treatments and technologies. This document
73 includes an overview of some of the considerations and concepts that may be relevant in
74 developing a harmonized assessment approach in future.

75
76 Technology has progressed from the time the original Global Harmonization Task Force (GHTF)
77 foundation documents were published. It is now possible to produce medical devices that are
78 individualized on a commercial rather than artisanal scale. Manufacturing technologies used to
79 create these PMDs include computer-controlled additive and subtractive manufacturing methods
80 based on patient images. The original GHTF documentation does not adequately address
81 medical devices of this nature.

82
83 Many jurisdictions already define the term *custom-made device* and have introduced exemption
84 provisions for regulating custom-made medical devices, with the intention of covering special
85 cases where commercially available products or alternative therapies are inadequate for the needs
86 and requirements of a particular individual. In some jurisdictions the exemption provisions were
87 based on the premise that affected devices would largely comprise low-risk products or limited
88 use of higher-risk implantable devices. In other jurisdictions the exemption provisions were
89 established with the intention that numbers of manufactured custom-made devices would
90 necessarily be small due to the requirement for them to be used only in special cases.

91
92 Now regulators are faced with a very different environment. Technologies such as additive and
93 subtractive manufacturing (see Appendix 1), especially when combined with digital patient data,
94 have made “custom-made” devices, including implantable devices, within reach on a much
95 greater scale. Furthermore, advancing technology has also enabled a shift to near or at point-of-
96 care manufacturing (collectively referred to as POC manufacturing throughout this document)
97 for manufacturing a broad range of medical devices not limited to PMDs only.

98
99 Existing regulations and guidance were not necessarily designed to address this form of
100 manufacturing and, consequently, present challenges for RAs to ensure that the medical devices
101 produced at POC manufacturing facilities meet the same requirements of quality, safety and
102 performance as medical devices produced at traditional manufacturing facilities. A secondary
103 purpose of this IMDRF guidance is to provide some considerations for how the current
104 regulatory frameworks can be adapted to address this evolution in manufacturing practices.

105
106

107 Note: This document is intended to provide a best-practice model for suitable regulatory
 108 pathways for different types of medical devices and is primarily intended to assist with
 109 harmonizing the regulation of PMDs across international jurisdictions.

110
 111 Individual jurisdictions may have particular requirements in place, which pre-date this guidance
 112 or that are more specific than this guidance, for some or all of the device categories represented.
 113

114 2.0 Scope

115 This document applies to all personalized medical devices (PMDs) and is intended to identify
 116 and describe different regulatory pathways and their requirements for the different categories of
 117 personalized devices that are defined in the IMDRF document N49, *Definitions for Personalized*
 118 *Medical Devices*. This document should be read in conjunction with N49.

119 Note that the concepts and regulatory approaches described in this document in relation to
 120 Medical Device Production Systems (MDPS) and POC manufacturing of medical devices, may
 121 also apply to a broad range of medical devices, and are not restricted to PMDs.

122 Excluded from the scope are *in vitro* diagnostic medical devices¹ (IVD MDs).

123

124 3.0 References

ISO/ASTM 52900:2015	Additive manufacturing — General principles — Terminology
GHTF/SG1/N071:2012	Definition of the Terms ‘Medical Device’ and ‘In Vitro Diagnostic (IVD) Medical Device’
IMDRF/PMD WG/N49 FINAL:2018	Definitions for Personalized Medical Devices
GHTF/SG1/N55:2009	Definitions of the Terms Manufacturer, Authorised Representative, Distributor and Importer
IMDRF/GRRP WG/N47 FINAL:2018	Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices
GHTF/SC/N4:2012	Glossary and definition of terms used in GHTF documents
IMDRF/GRRP WG/N52 FINAL:2019	Principles of Labelling for Medical Devices and IVD Medical Devices
GHTF/SG1/N78:2012	Principles of Conformity Assessment for Medical Devices
IMDRF/SaMD WG/ N10 FINAL:2013	Software as a medical device (SaMD): Key Definitions

125

¹ See *Definition of the Terms ‘Medical Device’ and ‘In Vitro Diagnostic (IVD) Medical Device’* (GHTF/SG1/N071:2012)

126 Note: Regulations and Guidance documents from the organizations represented by all working
127 group members were considered in the drafting of this document. For example:

128 Regulation (EU) 2017/745 of the European Parliament and of the Council of 5 April 2017
129 on medical devices

130 USFDA CDRH, Technical Considerations for Additive Manufactured Devices - Guidance
131 for Industry and Food and Drug Administration Staff, 5 Dec 2017

132 USFDA CDRH, Custom Device Exemption - Guidance for Industry and Food and Drug
133 Administration Staff, 24 Sept 2014

134

135 **4.0 Definitions²**

136 **4.1 custom-made medical device**—a medical device that, at a minimum, meets the
137 following requirements:

- 138 • it is intended for the sole use of a particular individual (which could be a patient or
139 healthcare professional); and
- 140 • it is specifically made in accordance with a written request of an authorized healthcare
141 professional, which gives, under their responsibility, specific design characteristics;
142 even though the design may be developed in consultation with a manufacturer; and
- 143 • it is intended to address the specific anatomic-physiological features or pathological
144 condition of the individual for whom it is intended.

145

146 Note 1: Medical devices that are patient-matched, adaptable or mass-produced shall not be
147 considered to be custom-made.

148

149 Note 2: A custom made device is intended for a case where an individual's specific needs
150 cannot be met, or cannot be met at the appropriate level of performance, by an alternative
151 device available on the market.

152

153 **4.2 patient-matched medical device**—a medical device that meets the following
154 requirements:

- 155 • it is matched to a patient's anatomy within a specified design envelope using
156 techniques such as scaling of the device based on anatomic references, or by using
157 the full anatomic features from patient imaging; and
- 158 • it is typically produced in a batch through a process that is capable of being
159 validated and reproduced; and

² For further information on personalized medical devices, including examples for definitions included in this document, and supporting definitions, see: IMDRF/PMD WG/N49 FINAL:2018 *Definitions for Personalized Medical Devices*

- 160
- 161 • it is designed and produced under the responsibility of a manufacturer even though
- 162 the design may be developed in consultation with an authorized healthcare
- 163 professional.

164 Note 1: A written request from an authorized healthcare professional may be present; but

165 is not mandatory.

166 Note 2: The number and type of design inputs in consultation with a healthcare

167 professional may vary depending on the medical devices to be manufactured.

168 Note 3: The design must remain within the validated parameters of the specified design

169 envelope.

170

171 **4.3 adaptable medical device**—a medical device that meets the following requirements:

- 172 • it is mass-produced; and
- 173 • it is adapted, adjusted, assembled or shaped at the point of care, in accordance with
- 174 the manufacturer’s validated instructions, to suit an individual patient’s specific
- 175 anatomy-physiologic features prior to use.

176 **4.4 Manufacturer**³

177 “Manufacturer” means any natural or legal person⁴ with responsibility for design and/or

178 manufacture of a medical device with the intention of making the medical device available

179 for use, under his name; whether or not such a medical device is designed and/or

180 manufactured by that person himself or on his behalf by another person(s).

181

182 **NOTES:**

- 183 1. This ‘natural or legal person’ has ultimate legal responsibility for ensuring
- 184 compliance with all applicable regulatory requirements for the medical device in the
- 185 countries or jurisdictions where it is intended to be made available or sold, unless this
- 186 responsibility is specifically imposed on another person by the Regulatory Authority
- 187 (RA) within that jurisdiction.
- 188 2. The manufacturer’s responsibilities are described in other GHTF guidance
- 189 documents. These responsibilities include meeting both pre-market requirements and
- 190 post-market requirements, such as adverse event reporting and notification of
- 191 corrective actions.
- 192 3. ‘Design and/or manufacture’, as referred to in the above definition, may include
- 193 specification development, production, fabrication, assembly, processing, packaging,

³ GHTF/SG1/N55:2009 *Definitions of the Terms Manufacturer, Authorised Representative, Distributor and Importer*


⁴ The term “person” that appears here and in the other definitions of this document, includes legal entities such as a corporation, a partnership, or an association.

- 194 repackaging, labelling, relabelling, sterilization, installation, or remanufacturing of a
195 medical device; or putting a collection of devices, and possibly other products,
196 together for a medical purpose.
- 197 4. Any person who assembles or adapts a medical device that has already been supplied
198 by another person for an individual patient, in accordance with the instructions for
199 use, is not the manufacturer, provided the assembly or adaptation does not change the
200 intended use of the medical device.
- 201 5. Any person who changes the intended use of, or modifies, a medical device without
202 acting on behalf of the original manufacturer and who makes it available for use
203 under his own name, should be considered the manufacturer of the modified medical
204 device.
- 205 6. An authorised representative, distributor or importer who only adds its own address
206 and contact details to the medical device or the packaging, without covering or
207 changing the existing labelling, is not considered a manufacturer.
- 208 7. To the extent that an accessory is subject to the regulatory requirements of a medical
209 device⁵, the person responsible for the design and/or manufacture of that accessory is
210 considered to be a manufacturer.
- 211
212
213

⁵ See GHTF/SG1/N29 *Information Document Concerning the Definition of the Term “Medical Device”*

214 **5.0 Decision Tree**

215
216



217 **6.0 Custom-made Medical Devices**

218 **Introduction**

219 Custom-made medical devices are intended to cover special cases where commercially available
220 products or alternative therapies are inadequate for meeting the needs and requirements of
221 particular individuals.

222
223 Many jurisdictions have addressed this challenge by implementing special regulatory pathways
224 for custom-made medical devices, which generally includes some exemptions from the usual
225 regulatory requirements to ensure that the specific needs of individuals are able to be met. The
226 pathways typically involve a requirement for an authorized healthcare professional to provide
227 design input and to take some of the responsibility normally placed on manufacturers for the
228 safety and performance of the finished medical devices.

229
230 The special regulatory pathways that many jurisdictions have for custom-made medical devices
231 are not intended for trialing new technologies—most jurisdictions have experimental and
232 investigation pathways for this purpose.

233

234 **General requirements**

235 The manufacturer of a custom-made medical device should first ensure that all elements of the
236 custom-made medical device definition are met; this includes obtaining the documented request
237 and specific design characteristics from an authorized healthcare professional⁶.

238

239 The manufacturer should then determine the classification the device would have were it not
240 custom-made and consider applying the equivalent regulatory requirements, according to the
241 device classification, of the jurisdiction in which it is to be supplied. All custom-made devices
242 should meet safety and performance requirements⁷.

243

244 Validated computational modelling and simulation methods, including reproducing the patient-
245 matched conditions to which the custom-made device will be exposed, may be one way to assess
246 the safety and performance of custom-made devices. Physical testing may also be appropriate.
247 The manufacturer should conduct a risk-analysis to determine the most appropriate methods to
248 employ.

249

250 Although professional and clinical responsibilities on the authorized healthcare professional do
251 not fall within the scope of this guidance document, in accordance with good medical practice, it
252 is expected that the authorized healthcare professional will be fully aware of the health-related
253 risks and benefits of the requested device in comparison to conventional therapies or alternative

⁶ An *authorized healthcare professional* is a person legally entitled to provide health services in the applicable jurisdiction.

⁷ IMDRF/GRRP WG/N47 FINAL:2018 *Essential Principles of Safety and Performance of Medical Devices and IVD Medical Devices*

254 devices available on the market. They should also be knowledgeable about the available safety
255 and performance information in respect of the requested device.

256
257 The meeting of the individual's specific needs, as translated by the specific design characteristics
258 provided by the authorized healthcare professional to the manufacturer, may lead to the
259 production of a custom-made medical device that does not fully comply with the usual safety and
260 performance requirements. The manufacturer should be required to document and justify such
261 non-compliance.

262
263 Note: It is expected that manufacturers will raise any concerns they may hold about the
264 implementation of the specific design characteristics with the authorized healthcare professional.
265

266 **Manufacturing and record keeping**

267 It is recommended that manufacturers be required to manufacture custom-made devices under a
268 quality management system (QMS). For higher risk custom-made devices, for example,
269 permanent implants, it is recommended that the QMS be subject to third-party oversight (e.g., an
270 auditing organization or regulatory agency).

271
272 The manufacturer should review the requirements and determine what is appropriate for their
273 custom-made devices in the jurisdictions where they will be supplied. Some important
274 considerations (by no means exhaustive) include:

- 275 • manufacturing impact on chemical, physical, and biological properties of the device;
- 276 • infection and microbial contamination control;
- 277 • method of sterilization;
- 278 • infrastructure and environment of manufacture;
- 279 • requirements for medical devices connected to or equipped with an energy source;
- 280 • maintenance of technical documentation and manufacturing records; and
- 281 • information supplied by the manufacturer, including labels and instructions for use.

282
283 It is recommended that the manufacturer be required to provide a statement with the custom-
284 made device; this statement should include:

- 285 • data allowing identification of the device, i.e., description, serial number, order number,
286 generic name;
- 287 • a section that indicates that the device is intended for exclusive use for a particular
288 individual, together with the name of the individual (this may be an identification number
289 if confidentiality needs to be maintained, provided it can be traced through records to the
290 named individual);
- 291 • the name of the authorized healthcare professional who requested the device, and, where
292 applicable, their place of work;
- 293 • the particular features of the device as specified in the relevant written request;
- 294 • a section that indicates that the device conforms to the relevant safety and performance
295 requirements; and, where it does not, which requirements are not fully met and the
296 grounds for believing that the device is nevertheless safe for use; and
- 297 • the name and address of the manufacturer.

298

299 Additionally, it is recommended that the manufacturer be required to:

- 300 • upon request, make documentation, including a copy of the written request and statement
301 to the regulatory authority. The documentation should allow an understanding of the
302 design, manufacture, and intended purpose of the custom-made device—so as to allow
303 assessment of conformity with regulatory requirements.
- 304 • retain the documentation for all implantable custom-made medical devices for a period of
305 at least 15 years or for the projected useful lifespan of the device, whichever is longer,
306 from the date of manufacture. For all other custom-made medical devices, the period
307 should be at least 5 years or for the projected useful lifespan of the device, whichever is
308 longer; and
- 309 • make the statement available to the requesting authorized healthcare professional and the
310 individual for whom the device has been manufactured.

311

312 **Registration or notification to regulatory authorities**

313 It is recommended that custom-made medical devices and their manufacturers or local
314 representatives be required to be registered or notified to the regulatory authority in the
315 jurisdiction in which they are supplied. Regulatory authorities should provide guidance on
316 registration or notification requirements, if any.

317

318 **Post-market surveillance, corrective action, and adverse-event reporting**

319 Manufacturers of custom-made devices should be required to review and document experience
320 gained in the post-production phase and set up a post-market surveillance system, including
321 reporting of adverse-events to authorities.

322

323 Responsible parties (for example, manufacturers, local representatives, or authorized healthcare
324 professionals) should follow applicable post-market requirements in their respective
325 jurisdictions; for example, reporting adverse events associated with the device, or conducting
326 field safety corrective actions (e.g., recalls).

327

328 Manufacturers should be required to investigate adverse-event reports, with the results of
329 investigations of any adverse-event reports that identify causes linked to the specific design
330 characteristics being fed back to the authorized healthcare professional who provided them.

331

332 Note: Ordinary return of devices to manufacturers for adjustment or fitting would not need to be
333 reported.

334

335 **7.0 Patient-matched Medical Devices**

336 **General requirements**

337 Patient-matched medical devices are designed and produced for a particular individual by a
338 manufacturer within validated parameters of a specified design envelope⁸. The variables within
339 the design envelope are predetermined by the manufacturer and not the authorized healthcare
340 professional.

341
342 Although design inputs, such as medical imaging or anatomic references, may be provided to the
343 manufacturer (e.g., by an individual or authorized healthcare professional), it is the manufacturer
344 that is responsible for matching the design of the device to the individual's anatomy, within the
345 design envelope, based on techniques such as scaling.

346
347 Patient-matched medical devices can be considered to be mass-produced devices, with
348 dimensional or other variations within a specified range.

349
350 The manufacturer of a patient-matched medical device must ensure the device is correctly
351 classified and must follow the usual regulatory requirements to obtain pre-market approval,
352 according to the risk classification, in the jurisdiction in which the devices are supplied.

353
354 The manufacturer must meet both pre- and post-market regulatory requirements in the
355 jurisdiction where the device is supplied; these might include, for example, clinical performance;
356 compliance with safety and performance standards; manufacturing standards; the provision of
357 labels and information; registration; and post-market surveillance, corrective action, and adverse-
358 event reporting.

359
360 Note: Relevant GHTF/IMDRF guidance documents are included in the references section above.
361

362 **Manufacturing and record keeping**

363 In order to demonstrate safety and performance for patient-matched medical devices, a
364 manufacturer must identify the maximum performance limits and limiting configurations in
365 terms of both parameters and manufacturing variables, for example, related to device geometry,
366 mechanical stress concentrations, energy power envelopes, material properties, or computational
367 power of the device. This is to ensure that any medical devices produced within the specified
368 design envelope comply with the relevant essential principles. This is a similar process used to
369 demonstrate safety and performance for mass-produced medical devices that are supplied in
370 different sizes.

371
372 Maximum performance limits and limiting configurations are commonly identified through the
373 manufacturer's risk-analysis process. Simulation and modelling methods, such as finite element
374 analysis, are sometimes useful for investigating the maximum performance limits and limiting
375 configurations.

⁸ The term 'specified design envelope' is defined in N49.

376
377 Standard methods of process validation and/or verification can also usually be applied for
378 determining performance limits and limiting configurations for manufacturing and design
379 variables; for example, testing of physical samples that represent worst-case scenarios (or
380 boundaries) within which the device will operate as intended.

381
382 The manufacturer should ensure that the technical documentation for patient-matched medical
383 devices includes records for the design envelope identification and validation process.

384
385 Additionally, it is recommended that the manufacturer be required to:

- 386 • maintain a copy of any written request(s) and other specification documentation that
387 includes the patient-matching information. For all implantable patient-matched medical
388 devices, the requirement should be for this information to be kept for a period of at least
389 15 years or for the projected useful lifespan of the device, whichever is longer, from the
390 date of manufacture. For all other patient-matched medical devices the period should be
391 at least 5 years or for the projected useful lifespan of the device, whichever is longer; and
- 392 • make the patient-matching information available to the named patient for whom the
393 device has been manufactured.

394

395 **8.0 Adaptable Medical Devices**

396 Adaptable medical devices are mass-produced and must follow the usual regulatory requirements
397 to obtain pre-market approval, according to their risk classification, in the jurisdiction in which
398 they are supplied.

399
400 The manufacturer must meet both pre- and post-market regulatory requirements in the
401 jurisdiction where the device is supplied; these might include, for example, clinical performance;
402 compliance with safety and performance standards; manufacturing standards; the provision of
403 labels and information; registration; and post-market surveillance, corrective action, and adverse-
404 event reporting. Note: Relevant GHTF/IMDRF guidance documents are included in the
405 references section above.

406
407 In addition to the usual requirements, the manufacturer of the adaptable medical device should
408 be required to provide *validated* instructions that explain how to adapt, adjust, assemble, or
409 shape the device. Development of the instructions should include suitable human factors
410 considerations in order to minimize safety issues that might result from the adaptation process.

411
412 The manufacturer's validation should:

- 413 • ensure that the permissible POC⁹ changes to the adaptable medical device do not
414 negatively affect the device's safety or performance;
- 415 • include, where applicable, analysis of allowable multi-component or multi-device
416 configurations; and

⁹ Note: It is acknowledged that the definition references 'POC'; however, in some jurisdictions, changes might be conducted after supply but prior to the point of care, for example, by a dispensing contractor. The adaptation might also be conducted by a patient or care giver.

- 417 • include consideration of human factors, particularly around an adapting entity’s ability to
418 suitably adapt, adjust, assemble, or shape the adaptable medical device.
419

420 The manufacturer may place requirements on the individual or entity who will be undertaking
421 the adaptation (the adapting entity), for example, requiring that verification testing be conducted
422 and that records be maintained. Records required to be maintained by the individual or entity
423 might include:

- 424 • identification of the device;
425 • where applicable, identification of the patient for whom the device was adapted;
426 • results of any verification testing; and
427 • any additional components or materials used as part of the adaptation.
428

429 The manufacturer may also consider the need for training of the adapting entity.
430

431 Note: it remains the manufacturer’s responsibility to ensure safety and performance of the
432 adaptable medical device.
433

434 **Appendix 1—Some considerations for medical devices produced using** 435 **additive or subtractive manufacturing**

436 **Introduction**

437 Additive and subtractive manufacturing are manufacturing methods that have existed for many
438 years; however, digital, and data-handling capabilities combined with increased availability of
439 affordable equipment, such as 3D printers, have resulted in the advent of technologies for the
440 ready production of a broad range of medical devices, including PMDs, by healthcare
441 professionals at POC manufacturing facilities or by traditional manufacturers.

442
443 This has raised questions about the suitability of these manufacturing methods for the production
444 of safe medical devices, particularly with respect to the validation of their design and production
445 methods; and the sufficiency of the quality control over any and all components, equipment, and
446 raw materials used for production purposes. Accordingly, a new concept is introduced—the
447 *medical device production system* (MDPS). Additionally, some considerations and guidance are
448 provided herein on:

- 449 • raw materials used for manufacture; and
- 450 • materials that are medical devices in their own right

451

452 **Medical device production systems**

453 If control over a manufacturing process, such as additive or subtractive manufacturing, outside of
454 a regulated manufacturing facility is needed, for example, for production of medical devices
455 above Class A¹⁰, jurisdictions may consider defining and regulating a ‘medical device
456 production system’ on the basis of the resultant medical device the system is intended to
457 produce, and any additional risks resulting from the POC production methods.

458

459 The manufacturer of an MDPS should be considered as a medical device manufacturer and will
460 be responsible for validating the intended use, the safety and performance of the devices which
461 can be produced at the POC using the MDPS. This includes validation of the design envelope for
462 patient-matched medical devices.

463

464 We define an MDPS as:

465


466 *A medical device production system* (MDPS) is a combination of the resultant medical
467 device and the medical device production process (MDPP) elements. The elements of an
468 MDPP includes the raw materials, software¹¹ and digital files, main production, and post-
469 processing (if applicable) equipment, and operating instructions intended to be used by
470 specific end users at a healthcare facility (HCF), to produce a specific type of medical device
471 for treating the patients of the HCF.

¹⁰2012 GHTF SG1 *Principles of Medical Devices Classification*

¹¹ Software used as part of production rather than software that meets the definition of a medical device in its own right.

- 472
- 473
- 474
- 475
- 476
- 477
- 478
- 479
- 480
- 481
- 482
- 483
- An MDPS includes the resultant medical device it is intended to produce and the intended use for the device validated in accordance with safety and performance requirements in the relevant regulatory jurisdiction.
 - An MDPS classification should be determined by the risk-based classification of the resultant medical device it is intended to produce, which may include consideration of any additional or likely foreseeable risks that may arise as a result of the operation of the MDPS.
 - An MDPS may require the use of ancillary equipment, human factors considerations, technical capability requirements, or other specified input and design limit controls; however, all components must be validated as a production process to consistently produce the resultant medical device with the use of the supplied operating instructions.

Medical Device Production System



484

485 Figure 1. An illustration of the constituent parts of a medical device production system (MDPS).

486

487 As shown in Figure 1, an MDPS has two primary constituents:

488

- 489
- 490
- 491
- 492
- 493
- 494
- 495
- Medical Device Production Process (MDPP) elements: which may include raw materials, main production and post-processing equipment, software and digital files, and the operating instructions supplied by the MDPS manufacturer to produce a specific medical device; and
 - Resultant Medical Device: the specific medical device that the MDPP produces using the operating instructions supplied by the MDPS manufacturer.

496 RAs having jurisdiction may consider an MDPS in accordance with the concept of a kit¹² or
497 system. That is, a group of products that together achieve a stated intended use—and as such,
498 can be considered a medical device in its own right.¹³ Consequently, all applicable elements of
499 the medical devices framework then apply to it. In this case, and if appropriate to the applicable
500 jurisdiction, the ‘medical device production system’ is not intended to be regulated as a
501 production tool for universal manufacture of medical devices as it would be if it were used for
502 production in a regulated manufacturing facility.

503
504 Jurisdictions may choose to introduce limits on the types of devices accepted for manufacture by
505 an MDPS, such as limiting them to low-risk products only; and they may also choose to impose
506 credentialing requirements for the use of an MDPS¹⁴.

507
508 The GHTF/IMDRF definition of ‘manufacturer’ applies to the manufacturer of an MDPS. This
509 allows for multiple OEMs and outsourcing to component manufacturers while one legal
510 manufacturer takes responsibility for MDPS. However, following the pre-market approval, and
511 as determined by the RA having jurisdiction, there may be different models under which an
512 MDPS manufacturer may supply its MDPS to an HCF:

- 513
514 a) Build, Own, Operate model: the MDPS manufacturer takes the responsibility for the
515 installation, ongoing maintenance including (but not limited to) supply of spare
516 parts and raw materials, and execution of the MDPP at the HCF. The MDPS
517 manufacturer takes the ongoing responsibility for the resultant medical devices that
518 the MDPP produces.
- 519 b) Build, Own, Operate, and Transfer model: the MDPS manufacturer takes the
520 responsibility for the installation, ongoing maintenance including (but not limited
521 to) supply of spare parts and raw materials to the HCF. The MDPS manufacturer
522 executes the MDPP for a period of time during which they take responsibility for
523 the resultant medical devices that the MDPP produces. At the predetermined time
524 and conditions, the ongoing responsibility for the resultant medical devices
525 produced by the MDPP thereafter is transferred to the HCF. Separate pre-market
526 approval for the resultant medical device may be required when the HCF assumes
527 the responsibility; however, depending on the jurisdictional requirements, an
528 abridged assessment could be undertaken leveraging the pre-market approval status
529 of the MDPS.
- 530 c) Build, Own, Transfer: the MDPS manufacturer takes the responsibility for the
531 installation, ongoing maintenance including (but not limited to) supply of spare
532 parts and raw materials to the HCF. The HCF takes the responsibility for the
533 resultant medical devices that the MDPP produces. The HCF may require separate
534 pre-market approval for the resultant medical device; however, depending on the

¹² GHTF/SC/N4:2012 *Glossary and definition of terms used in GHTF documents*

¹³ Jurisdictions not considering an MDPS (which includes the intended resulting medical devices) as a medical device, should introduce requirements for MDPS manufacturers on the quality, safety, and performance of the MDPS. Such requirements should include the obligation of the manufacturer to validate the MDPS and ensure conformity of the intended resultant medical devices with the Essential Principles.

¹⁴ Further information is provided in *Appendix 2(2)—Using Medical Device Production Systems*

535 jurisdictional requirements, an abridged assessment could be undertaken leveraging
536 the pre-market approval status of the MDPS.

537
538 As with all other medical devices, the manufacturer of an MDPS must identify and document
539 any necessary requirements regarding use of the MDPS. These might include, for instance,
540 environment controls; staff training and certification; conduction of verification testing; and
541 maintenance of records. Manufacturers should also establish methods for ensuring that the
542 necessary controls are implemented and that they remain effective over the lifetime of the
543 MDPP.

544
545 If the HCF or healthcare professional uses the MDPP to produce a device outside the original
546 manufacturer's intended use of the MDPS, then the user would take on all regulatory
547 responsibilities associated with the new intended use. In such instances, the user could be
548 considered a manufacturer in their own right and, consequently, all the requirements for
549 manufacturers would then apply to them.

550

551 **Raw materials for manufacture**

552 Raw materials for additive or subtractive manufacture, as with any other manufacturing raw
553 material, is not a medical device as it is not directly used for treating¹⁵ a patient, with limited
554 exceptions¹⁶. This is because regulating the raw material for a 3D-printer or CAD/CAM system
555 (for example) will not ensure that the final devices the system produces will comply with
556 applicable safety and performance requirements.

557
558 Additive and subtractive manufacture involves more than assembling or adapting a device for a
559 particular patient; it is a complex multifactorial process that has an impact on the finished
560 device's compliance with the essential principles. Consequently, instructions for use provided
561 by the manufacturer of a raw material for additive or subtractive manufacture cannot adequately
562 specify sufficient means of control over all of the variables in an additive or subtractive
563 manufacturing process.

564

565 **Materials that are medical devices**

566 According to the GHTF definition of medical device¹⁷, a 'material' can be a medical device in its
567 own right. An example of a 'material' regulated as a medical device in some jurisdictions is
568 dental resin materials used for restorations in the repair of teeth. A dentist assembles and/or
569 adapts the resin material for an individual patient, as intended by the manufacturer of the resin, in
570 accordance with the instructions for mixing, forming, curing, etc. the resin.

571 The assurance that the final assembled or adapted resin medical device will perform as intended
572 comes from the validated instructions provided by the manufacturer. This means that the resin

¹⁵ or any of the other medical device purposes in the GHTF definition of medical device

¹⁶ IMDRF/PMD WG/N58 Appendix 1 - Materials that are medical devices

¹⁷ GHTF/SG1/N071:2012 *Definition of the Terms 'Medical Device' and 'In Vitro Diagnostic (IVD) Medical Device'*

573 manufacturer will have tested the safety and performance of samples of its device, when adapted
574 or assembled according to its instructions. The manufacturer makes certain specifications for the
575 use of its product, such as the mixing constituents, the mixing ratio, the type and size of defect to
576 which the resin should be applied and how long it needs to cure. When the dentist follows these
577 instructions, the dental resin restoration will perform as intended by the manufacturer of the
578 resin. It is important to note that the material regulated as a medical device is only to be used for
579 the specific intended use identified and not for unlimited intended uses for other medical devices
580 that have not been validated for safety and performance.
581

Final Working Draft

582 **Appendix 2—Considerations for point-of-care manufacture of medical devices**

583 **Introduction**

584 HCFs or healthcare professionals may be involved in manufacturing of medical devices,
585 including PMDs, for use in treating their patients. Medical device manufacturing usually occurs
586 under appropriate quality management systems, and in regulated manufacturing facilities. Under
587 the GHTF model, it is recognized that appropriate regulatory oversight of medical device
588 manufacturers is an important factor in ensuring safety and performance of medical devices. For
589 this reason, there should also be an oversight of manufacturing that is occurring in alternative
590 locations such as at the POC.

591 Traditionally, POC manufacturing has been limited in scope; however, advances in technology
592 have enabled the manufacture of more complex, higher-risk medical devices including PMDs by
593 healthcare professionals (on a routine basis) without the usual requirements and oversight that
594 traditional manufacturers are typically subject to.

595 Oversight of HCFs and healthcare professionals varies in different jurisdictions around the
596 world, from full regulation of them as regulated entities (as traditional manufacturers), through to
597 pathways that allow for exemption under certain criteria (for example, when medical devices
598 including PMDs are manufactured at HCFs or by recognized healthcare professionals).

599 The following sub-sections in this Appendix include recommendations for three possible
600 approaches that regulators might choose to implement for regulatory oversight of medical device
601 manufacturing at or near the POC. These are:

- 602 1. Manufacturing under special arrangements
- 603 2. Using Medical Device Production Systems
- 604 3. Fully regulated manufacturing (as per the GHTF/IMDRF model)

605 **1. Manufacturing under special arrangements**

606 Introduction

607 Some jurisdictions apply different regulatory frameworks (such as exemptions or special
608 provisions) for medical device manufacturing undertaken in HCF, or by healthcare professionals,
609 as compared to manufacturing undertaken by traditional manufacturers. The different
610 frameworks tend to be limited to medical devices intended to address indispensable clinical
611 needs within specific institutions or their network of subsidiary or partner institutions.

612 Any exemptions for manufacturing within a HCF should not apply to establishments primarily
613 claiming to pursue health interests or healthy lifestyles, such as gyms, spas, wellness, and fitness
614 centers, or to establishments focused on beauty treatments such as cosmetic clinics.

615 Protection of safety and performance

616 When HCFs or healthcare professionals design and/or manufacture a medical device under
617 special arrangements, including at the POC, it is recommended that they be required to protect
618 patient safety, and ensure appropriate performance of the medical device, by meeting certain
619 imposed requirements that include the following:

- 620 a) the manufacture and use of the devices to be undertaken under an appropriate quality
621 management system;
- 622 b) the HCF or healthcare professional to be required to have on file, and to provide
623 information upon request, on the use of devices it has manufactured to its
624 regulatory authority. The information should include a justification of the
625 indispensable clinical needs warranting manufacture of the device and details of
626 their manufacture, including appropriate quality management validation
627 documentation, device designs or modifications, and the intended use;
- 628 c) the HCF or healthcare professional to be required to make available to the RA having
629 jurisdiction or the patient receiving the device the following information:
- 630 i. the name and address of the manufacturing HCF or healthcare professional;
- 631 ii. the details necessary to identify the device;
- 632 iii. a declaration that the device meets general safety principles and, where
633 applicable, information on which principles have not been fully met together
634 with a reasoned justification thereof;
- 635 d) the HCF or healthcare professional to be required to draw up documentation under its quality
636 management system that makes it possible to have an understanding of the manufacturing
637 facility; the manufacturing process; and the design and data providing confidence that the
638 device will function as intended, including the intended purpose, and that is sufficiently
639 detailed to enable the regulatory authority to ascertain that the general safety and
640 performance requirements have been met;
- 641 e) the HCF or healthcare professional to be required to take all necessary measures to
642 ensure that all devices it manufactures are manufactured in accordance with the
643 documentation referred to in point (d);
- 644 f) the HCF or healthcare professional to be required to review experience gained from
645 clinical use of all devices it manufactures, report any adverse events to the
646 regulatory authority, and take all necessary corrective and preventive actions; and
- 647 g) the HCF will allow the regulatory authority to inspect the manufacturing processes
648 when appropriate.
649

650 Regulators who apply special frameworks for the manufacture of medical devices within a HCF,
651 or by healthcare professionals, should consider including regulatory oversight commensurate
652 with that of the equivalent frameworks in place for traditional manufacturers. For instance, a
653 hospital may be required to operate under a quality management system certified by a competent
654 3rd party and be required to meet, and be assessed against, appropriate safety and other technical
655 standards that are equivalent to the essential principles of safety and performance.

656

657 **2. Using Medical Device Production Systems¹⁸**

658 The manufacturer of an MDPS is responsible for conducting validation activities and
659 maintaining relevant documentation in relation to the MDPP and the resultant medical device.

¹⁸ This is introduced in Appendix 1

660
661 The MDPS manufacturer is further responsible for all pre-market approval activities, and
662 depending on the jurisdictional requirements, the manufacturer may be required to register the
663 MDPS and the resultant medical device separately. Following the pre-market approval, the RA
664 having jurisdiction may consider placing additional responsibilities on the MDPS manufacturer,
665 including (but not limited to) systematically collecting post-market user data for the MDPP, post-
666 market adverse-event reporting for the resultant medical device, advertisement compliance, and
667 maintaining production and supply records.

668
669 Following pre-market approval, the supply of an MDPS to the HCF may occur under different
670 arrangements (as explained in Appendix 1) depending on the contractual agreements between the
671 manufacturer and the HCF.

672
673 In some regulatory jurisdictions, when the HCF takes the responsibility for the resultant medical
674 device that an MDPP is intended to produce, the HCF may be required to obtain separate pre-
675 market approval for the resultant medical device before the device can be supplied for use in the
676 patients of the HCF. Depending on the requirements of the RA having jurisdiction, an abridged
677 assessment for the resultant medical device may be undertaken leveraging the pre-market
678 approval status of the MDPS. Following the pre-market approval, the HCF could have ongoing
679 regulatory obligations to meet, including (but not limited to) supplying devices with appropriate
680 labelling, post-market adverse-event reporting, advertisement compliance, and maintaining
681 production and supply records.

682 **3. Fully regulated manufacturing (as per the GHTF/IMDRF model)**

683 In this case, the regulator treats HCFs and healthcare professionals that/who undertake
684 manufacturing the same way they treat traditional manufacturers.

685
686 These ‘POC manufacturers’ need to ensure their medical devices are correctly classified and
687 follow the usual regulatory requirements to obtain pre-market approval according to the risk
688 classification in the jurisdiction in which the devices are supplied.

689
690 Manufacturers are required to meet both pre- and post-market regulatory requirements in the
691 jurisdiction where their medical devices are supplied; these might include, for example,
692 implementation of appropriate quality management systems; generation of clinical evidence;
693 compliance with safety and performance standards; design; testing; manufacturing standards;
694 undertake supplier control (including outsourcing¹⁹ of different elements of manufacture); the
695 provision of labels and information; registration; and post-market surveillance, corrective action,
696 and adverse-event reporting.

697
698 Note: Relevant GHTF/IMDRF guidance documents are included in the references section above.
699

¹⁹ The GHTF/IMDRF definition of ‘manufacturer’ allows for outsourcing of different manufacturing steps (including testing, validation, and sterilization) to third parties while the ‘manufacturer’, in this case the HCF or healthcare professional, takes legal responsibility for the entire quality management system and the medical devices manufactured under it.